DrugId:  1
1. Name:  BCG vaccine
2. Groups:  Investigational
3. Description:  BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
4. Indication:  Not Available
DrugId:  2
1. Name:  Metrizamide
2. Groups:  Approved
3. Description:  Metrizamide is a solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity. It is also used as a resorbable, non-ionic contrast medium.
4. Indication:  Metrizamide is used for lumbar, thoracic, cervical, and total columnar myelography to determine the presence of abnormalities in the spinal column, spinal canal, and central nervous system (CNS) as well as for cisternography by direct injection using standard radiologic techniques to visualize the basal cistern of the brain. For computerized tomography (CT) of the intracranial subarachnoid spaces and for ventriculography by direct injection using standard radiologic techniques to visualize the cerebral ventricles. Also used in pediatric angiocardiography to visualize lesions or malformations of the heart and obstructions or anomalies of the major thoracic vessels. Also used in adult peripheral arteriography to visualize specific regions of the vascular system and blood flow in such areas to help in the diagnosis and evaluation of neoplasms (known or suspected) or vascular diseases (congenital or acquired) that may cause changes in normal vascular anatomy or physiology. Metrizamide is also indicated in adults for intravenous digital arteriography of head and neck.
DrugId:  3
1. Name:  Enfortumab vedotin
2. Groups:  Investigational
3. Description:  Enfortumab vedotin has been used in trials studying the treatment of Tumors, Neoplasms, and Medical Oncology.
4. Indication:  Not Available
DrugId:  4
1. Name:  Patritumab
2. Groups:  Investigational
3. Description:  Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.
4. Indication:  Not Available
DrugId:  5
1. Name:  5-fluoro-2'-deoxycytidine
2. Groups:  Investigational
3. Description:  5-fluoro-2'-deoxycytidine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, and Urinary Bladder Neoplasms, among others.
4. Indication:  Not Available
DrugId:  6
1. Name:  Prednisone
2. Groups:  Approved, Vet approved
3. Description:  A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver. [PubChem]
4. Indication:  For the treatment of drug-induced allergic reactions, perennial or seasonal allergic rhinitis, serum sickness, giant cell arteritis acute rheumatic or nonrheumatic carditis, systemic dermatomyositis, systemic lupus erythematosus, atopic dermatitis, contact dermatitis, exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe (Stevens-Johnson syndrome) erythema multiforme, mycosis fungoides, pemphigus, severe psoriasis, acute adrenocortical insufficiency, Addison's disease, secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with neoplasms, nonsuppurative thyroiditis, ulceratice colitis, Crohn's disease, acquired hemolytic anemia, congenital hypoplastic anemia, erythroblastopenia, adult secondary thrombocytopenia, adult idiopathic thrombocytopenia purpura, acute or subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute or chronic lymphocytic leukemia, Hodgkin's or non-Hodgkin's lynphomas, Waldenstrom's macroglobulinemia, primary brain tumors (adjunct), nephrotic syndrome, tuberculous meningitis, multiple sclerosis, myasthenia gravis. cerebral edema, chorioretinitis, diffuse posterior choroiditis, aleergic conjunctivitis, Herpes zoster ophthalmicus, anterior segment inflammation, iridocyclitis, iritis, keratitis, optoc neuritis, sympathetic ophthalmia, corneal marginal allergic ulcers, symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy and aspiration pneumonitis.
DrugId:  7
1. Name:  Figitumumab
2. Groups:  Investigational
3. Description:  Figitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others.
4. Indication:  Not Available
DrugId:  8
1. Name:  Ganitumab
2. Groups:  Investigational
3. Description:  Ganitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others.
4. Indication:  Not Available
DrugId:  9
1. Name:  Amatuximab
2. Groups:  Investigational
3. Description:  Amatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Pancreatic Cancer, and Mesothelioma, Malignant, among others.
4. Indication:  Not Available
DrugId:  10
1. Name:  Lumretuzumab
2. Groups:  Investigational
3. Description:  Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
4. Indication:  Not Available
DrugId:  11
1. Name:  Onartuzumab
2. Groups:  Investigational
3. Description:  Onartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others.
4. Indication:  Not Available
DrugId:  12
1. Name:  Duligotuzumab
2. Groups:  Investigational
3. Description:  Duligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant.
4. Indication:  Not Available
DrugId:  13
1. Name:  Ascrinvacumab
2. Groups:  Investigational
3. Description:  Ascrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.
4. Indication:  Not Available
DrugId:  14
1. Name:  Exametazime
2. Groups:  Approved
3. Description:  Exametazime is a diagnostic radiopharmaceutical agent commonly used for the preparation of Tc99m Exametazime injection. It acts as a chelating agent for the radioisotope technetium-99m to form a cationic complex. It is used in the detection of altered regional cerebral perfusion and for the radiolabeling of autologous leukocytes.
4. Indication:  Not Available
DrugId:  15
1. Name:  QR-334
2. Groups:  Investigational
3. Description:  QR-334 is under investigation for the treatment of sialorrhea. Sialorrhea is an excess secretion of saliva produced by the salivary glands, resulting in drooling. No pharmaceutical interventions currently exist to treat sialorrhea. The symptom is associated with many diseases including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrigâ€™s Disease, Cerebral Palsy, Parkinson's Disease, and Muscular Dystrophy.
4. Indication:  Investigated for use/treatment in saliva and salivary gland dysfunction (sialorrhea).
DrugId:  16
1. Name:  Nerve Growth Factor
2. Groups:  Investigational
3. Description:  Nerve Growth Factor has been used in trials studying the prevention and treatment of Mental Handicap, Alzheimer's Disease, Traumatic Brain Injury, Cerebral Palsy Children, and Delayed Speech Development, among others.
4. Indication:  Not Available
DrugId:  17
1. Name:  Atamestane
2. Groups:  Investigational
3. Description:  Atamestane has been used in trials studying the treatment of Breast Cancer, Breast Neoplasms, and Neoplasms, Hormone-Dependent.
4. Indication:  Not Available
DrugId:  18
1. Name:  AZD-1305
2. Groups:  Investigational
3. Description:  AZD1305 has been used in trials studying the treatment and basic science of Atrial Flutter, Atrial Fibrillation, and Left Ventricle Function.
4. Indication:  Not Available
DrugId:  19
1. Name:  LIC-477
2. Groups:  Investigational
3. Description:  LIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity. 
4. Indication:  Investigated for use/treatment in bipolar disorders.
DrugId:  20
1. Name:  ZD-6126
2. Groups:  Investigational
3. Description:  ZD6126 has been used in trials studying the treatment of Kidney Neoplasms, Colorectal Neoplasms, Metastases, Neoplasm, and Carcinoma, Renal Cell.
4. Indication:  Not Available
DrugId:  21
1. Name:  Mitometh
2. Groups:  Investigational
3. Description:  Mitometh is under investigation for the treatment of Adenocarcinoma, Oropharyngeal Neoplasms, Nasopharyngeal Carcinoma, Non-small Cell Lung Cancer, and Stage IV Non-small Cell Lung Cancer, among others. Mitometh has been investigated for the treatment of Lung Neoplasms, Untreated Childhood Medulloblastoma, and Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor.
4. Indication:  Not Available
DrugId:  22
1. Name:  CP-547632
2. Groups:  Investigational
3. Description:  CP-547632 has been used in trials studying the treatment of Ovarian Cancer, Lung Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, and Fallopian Tube Cancer, among others.
4. Indication:  Not Available
DrugId:  23
1. Name:  APR-246
2. Groups:  Investigational
3. Description:  APR-246 has been used in trials studying the treatment of Prostatic Neoplasms, Hematologic Neoplasms, and Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53.
4. Indication:  Not Available
DrugId:  24
1. Name:  Tetrahydrouridine
2. Groups:  Investigational
3. Description:  Tetrahydrouridine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms, Breast Neoplasms, Sickle Cell Disease, and Head and Neck Cancer, among others.
4. Indication:  Not Available
DrugId:  25
1. Name:  Lapachone
2. Groups:  Investigational
3. Description:  Lapachone has been used in trials studying the treatment of Cancer, Carcinoma, Advanced Solid Tumors, Head and Neck Neoplasms, and Carcinoma, Squamous Cell.
4. Indication:  Not Available
